Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

Merck's expansion into cardiovascular treatments and advancements in immunology and inflammation, partly through the Prometheus transaction, are seen as potential growth drivers by analysts.

like acquiring Acceleron and Prometheus, and cautious, like passing on Seagen due to valuation concerns. BofA Securities writes Merck stock's valuation was too low for an above-average growth profile.

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

MSD – known as Merck & Co in North America – acquired rights to PRA023 (now MK-7240) when it bought Prometheus Biosciences for $10.8 billion earlier this year, while Roche was recently ...

MSD, known as Merck & Co in the US and Canada ... notably buying Acceleron for $11.5 billion in 2021 and Prometheus for $10.8 billion a year later, along with several smaller-scale deals.

Merck's expansion into cardiovascular treatments and advancements in immunology and inflammation, partly through the Prometheus transaction, are seen as potential growth drivers by analysts. In the ...

1 Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada 2 Department of Medicine, University of Western Ontario, London, Ontario, Canada Objective ...